$NKTR (Nektar Therapeutics)

$NKTR {{ '2016-02-01T16:22:10+0000' | timeago}} • Announcement

$NKTR said it published pre-clinical results for NKTR-214, an investigational CD122-biased immune-stimulatory cytokine for the treatment of cancer in Clinical Cancer Research. The new paper documents durable anti-tumor efficacy, safety and immune mechanism of action of NKTR-214 in multiple tumor models.

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$CELG {{ '2018-01-22T13:26:32+0000' | timeago}} • Announcement

Last week's rumor becomes reality. $CELG to acquire its strategic partner $JUNO for $9Bil. Juno Therapeutics, which had already skyrocketed nearly 50% in the last week, has increased more than 25% today in pre-market from Jan. 19th closing price of $67.81. Celgene expects that this deal will help it to boost the revenue generation beyond 2020.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$MRK {{ '2018-01-09T20:27:32+0000' | timeago}} • Announcement

Pharma company $MRK said the FDA has granted 'Breakthrough Therapy Designation' for Lenvima, a multiple receptor tyrosine kinase inhibitor developed by Eisai in combination with Merck's anti-PD-1 therapy Keytruda for the treatment of renal cell carcinoma. The FDA action was based on the results of a multi-center study conducted in US and Europe.

$MRK {{ '2018-01-09T18:45:44+0000' | timeago}} • Announcement

Merck today announced that it has received Breakthrough Therapy Designation from FDA for LENVIMA and KEYTRUDA. The combination therapy (LENVIMA & KEYTRUDA) is being jointly developed by Eisai and $MRK for treating patients with advanced and/or metastatic renal cell carcinoma. In 2017, approx. 63,990 new cases were estimated to have occurred in US.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$MRK {{ '2018-01-02T20:34:14+0000' | timeago}} • Announcement

Merck announced today that Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its cancer drug KEYTRUDA for treating patients with Urothelial Carcinoma, a type of bladder cancer. This approval helps $MRK to market KEYTRUDA for 4 types of cancer in Japan. The company plans to market KEYTRUDA in partnership with Taiho Pharmaceuticals.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$BDX {{ '2017-12-29T16:54:30+0000' | timeago}} • Announcement

$BDX acquired $BCR. Beginning with 2Q18, $BDX will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment.

$BDX {{ '2017-12-29T16:54:14+0000' | timeago}} • Announcement

$BDX has acquired $BCR. $BDX does not expect the acquisition to have a material impact on its financial results in 1Q18. $BDX expects the transaction to generate low-single digit accretion to adjusted EPS in FY18, and high-single digit accretion in FY19.

$BDX {{ '2017-12-29T16:53:59+0000' | timeago}} • Announcement

$BDX completed the acquisition of $BCR. Under the terms of the transaction, Bard became a wholly owned subsidiary of $BDX, and each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of $BDX common stock. Bard shares will cease trading and be delisted from the NYSE.

$BDX {{ '2017-12-28T12:35:48+0000' | timeago}} • Announcement

$BDX gets clearance from the Ministry of Commerce of the People's Republic of China (MOFCOM) to acquire $BCR. BD and Bard expect the proposed acquisition to close on Dec. 29. Separately, BD's proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
INSM (Insmed Incorporated)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like